Your browser doesn't support javascript.
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.
Caniels, Tom G; Bontjer, Ilja; van der Straten, Karlijn; Poniman, Meliawati; Burger, Judith A; Appelman, Brent; Lavell, A H Ayesha; Oomen, Melissa; Godeke, Gert-Jan; Valle, Coralie; Mögling, Ramona; van Willigen, Hugo D G; Wynberg, Elke; Schinkel, Michiel; van Vught, Lonneke A; Guerra, Denise; Snitselaar, Jonne L; Chaturbhuj, Devidas N; Cuella Martin, Isabel; Moore, John P; de Jong, Menno D; Reusken, Chantal; Sikkens, Jonne J; Bomers, Marije K; de Bree, Godelieve J; van Gils, Marit J; Eggink, Dirk; Sanders, Rogier W.
  • Caniels TG; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Bontjer I; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • van der Straten K; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Poniman M; Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Burger JA; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Appelman B; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Lavell AHA; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Oomen M; Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Godeke GJ; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Valle C; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • Mögling R; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • van Willigen HDG; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • Wynberg E; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Schinkel M; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • van Vught LA; Public Health Service of Amsterdam, Amsterdam, Netherlands.
  • Guerra D; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Snitselaar JL; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Chaturbhuj DN; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Cuella Martin I; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Moore JP; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Reusken C; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, USA.
  • Sikkens JJ; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Bomers MK; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • de Bree GJ; Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • van Gils MJ; Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Eggink D; Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
  • Sanders RW; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
Sci Adv ; 7(36): eabj5365, 2021 Sep 03.
Article in English | MEDLINE | ID: covidwho-1403006
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Emerging SARS-CoV-2 variants of concern (VOCs) pose a threat to human immunity induced by natural infection and vaccination. We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50). Spike binding and neutralization against all three VOCs were substantially reduced in most individuals, with the largest four- to sevenfold reduction in neutralization being observed against B.1.351. While hospitalized patients with COVID-19 and vaccinees maintained sufficient neutralizing titers against all three VOCs, 39% of nonhospitalized patients exhibited no detectable neutralization against B.1.351. Moreover, monoclonal neutralizing antibodies show sharp reductions in their binding kinetics and neutralizing potential to B.1.351 and P.1 but not to B.1.1.7. These data have implications for the degree to which pre-existing immunity can protect against subsequent infection with VOCs and informs policy makers of susceptibility to globally circulating SARS-CoV-2 VOCs.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal: Sci Adv Year: 2021 Document Type: Article Affiliation country: Sciadv.abj5365

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal: Sci Adv Year: 2021 Document Type: Article Affiliation country: Sciadv.abj5365